Percutaneous ablation of hepatocellur carcinoma: State-of-the-art

Riccardo Lencioni, Dania Cioni, Laura Cricetti, Carlo Bartolozzi

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Percutaneous ablation is considered the best treatment option for patients with early-stage hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation. Several methods have been developed, including intratumoral injection of ethanol or acetic acid, and thermal ablation with radiofrequency, laser, microwaves, or cryosurgery. Percutaneous ethanol injection (PEI) has been the most widely used technique. Several series have provided indirect evidence that PEI improves the natural history of HCC. Patients with Child-Pugh class A cirrhosis and either a single tumor smaller than 5 cm or as many as three lesions each smaller than 3 cm may achieve a 5-year survival of 50%. The major limitation of PEI is the high local recurrence rate, which may reach 33-43%. Radiofrequency (RF) ablation has emerged as the most powerful alternate method for percutaneous ablation. Recent studies have shown that RF ablation can achieve more effective local tumor control than PEI with fewer treatment sessions. In a randomized trial, local recurrence-free survival rates were significantly higher in patients who received RF ablation than in those treated by PEI, and treatment allocation was confirmed as an independent prognostic factor by multivariate analysis. RF ablation could therefore be considered as the percutaneous treatment of choice for patients with early-stage tumors. Further investigation is warranted to clarify whether current RF technology could offer improved results in patients with intermediate-stage HCC.

Original languageEnglish (US)
JournalLiver Transplantation
Volume10
Issue number2 SUPPL. 1
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Ethanol
Carcinoma
Injections
Hepatocellular Carcinoma
Recurrence
Neoplasms
Cryosurgery
Therapeutics
Microwaves
Acetic Acid
Liver Transplantation
Statistical Factor Analysis
Lasers
Fibrosis
Multivariate Analysis
Survival Rate
Hot Temperature
Technology
Survival

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Lencioni, R., Cioni, D., Cricetti, L., & Bartolozzi, C. (2004). Percutaneous ablation of hepatocellur carcinoma: State-of-the-art. Liver Transplantation, 10(2 SUPPL. 1).

Percutaneous ablation of hepatocellur carcinoma : State-of-the-art. / Lencioni, Riccardo; Cioni, Dania; Cricetti, Laura; Bartolozzi, Carlo.

In: Liver Transplantation, Vol. 10, No. 2 SUPPL. 1, 02.2004.

Research output: Contribution to journalArticle

Lencioni, R, Cioni, D, Cricetti, L & Bartolozzi, C 2004, 'Percutaneous ablation of hepatocellur carcinoma: State-of-the-art', Liver Transplantation, vol. 10, no. 2 SUPPL. 1.
Lencioni R, Cioni D, Cricetti L, Bartolozzi C. Percutaneous ablation of hepatocellur carcinoma: State-of-the-art. Liver Transplantation. 2004 Feb;10(2 SUPPL. 1).
Lencioni, Riccardo ; Cioni, Dania ; Cricetti, Laura ; Bartolozzi, Carlo. / Percutaneous ablation of hepatocellur carcinoma : State-of-the-art. In: Liver Transplantation. 2004 ; Vol. 10, No. 2 SUPPL. 1.
@article{dc66e6dcdddb49aab4ee37991724b0db,
title = "Percutaneous ablation of hepatocellur carcinoma: State-of-the-art",
abstract = "Percutaneous ablation is considered the best treatment option for patients with early-stage hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation. Several methods have been developed, including intratumoral injection of ethanol or acetic acid, and thermal ablation with radiofrequency, laser, microwaves, or cryosurgery. Percutaneous ethanol injection (PEI) has been the most widely used technique. Several series have provided indirect evidence that PEI improves the natural history of HCC. Patients with Child-Pugh class A cirrhosis and either a single tumor smaller than 5 cm or as many as three lesions each smaller than 3 cm may achieve a 5-year survival of 50{\%}. The major limitation of PEI is the high local recurrence rate, which may reach 33-43{\%}. Radiofrequency (RF) ablation has emerged as the most powerful alternate method for percutaneous ablation. Recent studies have shown that RF ablation can achieve more effective local tumor control than PEI with fewer treatment sessions. In a randomized trial, local recurrence-free survival rates were significantly higher in patients who received RF ablation than in those treated by PEI, and treatment allocation was confirmed as an independent prognostic factor by multivariate analysis. RF ablation could therefore be considered as the percutaneous treatment of choice for patients with early-stage tumors. Further investigation is warranted to clarify whether current RF technology could offer improved results in patients with intermediate-stage HCC.",
author = "Riccardo Lencioni and Dania Cioni and Laura Cricetti and Carlo Bartolozzi",
year = "2004",
month = "2",
language = "English (US)",
volume = "10",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Percutaneous ablation of hepatocellur carcinoma

T2 - State-of-the-art

AU - Lencioni, Riccardo

AU - Cioni, Dania

AU - Cricetti, Laura

AU - Bartolozzi, Carlo

PY - 2004/2

Y1 - 2004/2

N2 - Percutaneous ablation is considered the best treatment option for patients with early-stage hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation. Several methods have been developed, including intratumoral injection of ethanol or acetic acid, and thermal ablation with radiofrequency, laser, microwaves, or cryosurgery. Percutaneous ethanol injection (PEI) has been the most widely used technique. Several series have provided indirect evidence that PEI improves the natural history of HCC. Patients with Child-Pugh class A cirrhosis and either a single tumor smaller than 5 cm or as many as three lesions each smaller than 3 cm may achieve a 5-year survival of 50%. The major limitation of PEI is the high local recurrence rate, which may reach 33-43%. Radiofrequency (RF) ablation has emerged as the most powerful alternate method for percutaneous ablation. Recent studies have shown that RF ablation can achieve more effective local tumor control than PEI with fewer treatment sessions. In a randomized trial, local recurrence-free survival rates were significantly higher in patients who received RF ablation than in those treated by PEI, and treatment allocation was confirmed as an independent prognostic factor by multivariate analysis. RF ablation could therefore be considered as the percutaneous treatment of choice for patients with early-stage tumors. Further investigation is warranted to clarify whether current RF technology could offer improved results in patients with intermediate-stage HCC.

AB - Percutaneous ablation is considered the best treatment option for patients with early-stage hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation. Several methods have been developed, including intratumoral injection of ethanol or acetic acid, and thermal ablation with radiofrequency, laser, microwaves, or cryosurgery. Percutaneous ethanol injection (PEI) has been the most widely used technique. Several series have provided indirect evidence that PEI improves the natural history of HCC. Patients with Child-Pugh class A cirrhosis and either a single tumor smaller than 5 cm or as many as three lesions each smaller than 3 cm may achieve a 5-year survival of 50%. The major limitation of PEI is the high local recurrence rate, which may reach 33-43%. Radiofrequency (RF) ablation has emerged as the most powerful alternate method for percutaneous ablation. Recent studies have shown that RF ablation can achieve more effective local tumor control than PEI with fewer treatment sessions. In a randomized trial, local recurrence-free survival rates were significantly higher in patients who received RF ablation than in those treated by PEI, and treatment allocation was confirmed as an independent prognostic factor by multivariate analysis. RF ablation could therefore be considered as the percutaneous treatment of choice for patients with early-stage tumors. Further investigation is warranted to clarify whether current RF technology could offer improved results in patients with intermediate-stage HCC.

UR - http://www.scopus.com/inward/record.url?scp=1342347891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342347891&partnerID=8YFLogxK

M3 - Article

C2 - 14762847

AN - SCOPUS:1342347891

VL - 10

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 2 SUPPL. 1

ER -